RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Adlai Nortye, a Hangzhou company, entered a $86.6 million iin-licensing agreement to develop and market a novel immuno-oncolytic virus in Greater China that was discovered by Canada’s Oncolytics Biotech®. Reolysin® is an intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems. Oncolytics plans a US Phase III trial of Reolysin in patients with HR+/HER2 metastatic breast cancer. Adlai Nortye will be responsible for all China clinical development of the candidate.
Source: China Biotoday
